微RNA-1307-3p通过PRM2促进乳腺癌的进展
José Roberto Estupiñan-Jiménez1, Valeria Villarreal-García1, Vianey Gonzalez-Villasana1
1Departmento de Biología Celular y Genética, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico.
Thoracic cancer
|October 9, 2024
概括
微RNA miR-1307-3p促进乳腺癌 (BC) 的生长和扩散. 抑制这种微RNA并准其新型基因 - - 蛋白胺2 (PRM2) 可能为BC.提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 乳腺癌 (BC) 仍然是全球女性的主要癌症.
- 微RNA (miRNA) 失调与BC发育有关.
- miR-1307-3p在BC上调调节,但其功能和目标尚未完全理解.
研究的目的:
- 研究miR-1307-3p在BC细胞增殖,迁移,入侵和血管生成中的作用.
- 在BC.中识别和验证miR-1307-3p的基因.
主要方法:
- 定量实时逆转录PCR (RT-qPCR) 用于测量miR-1307-3p水平.
- 在miR-1307-3p抑制后评估BC细胞行为.
- 生物信息分析和实验验证 (西布洛特,双露西法酶试验) 以识别和确认miR-1307-3p目标.
主要成果:
- 抑制miR-1307-3p显著抑制BC细胞的增殖,迁移,入侵和血管生成.
- 生物信息学预测了miR-1307-3p.p.的17个潜在目标.
- 质氨酸2 (PRM2) 被证实是miR-1307-3p的直接标基因.
结论:
- 过度表达miR-1307-3p驱动乳腺癌进展的关键特征.
- 在乳腺癌的背景下,PRM2被确定为miR-1307-3p的新目标.
- 针对miR-1307-3p及其下游效应器,如PRM2,可能是BC的治疗途径.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Nucleolus
8.7K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


